The Economic Times

October 22, 2003

Sami Labs gets three patents

SAMI LABS, a Bangalore based Rs 250- crore health biotech company, has been granted three patents for new active ingredients in the filed of dermatology, ineffective and geriatric ophthalmology, which will help in its effort to become a more serious global player. The patents will pave way for a renewed focus on discovery and intellectual property, Dr Muhammed Majeed, chairman and managing director, Sami Labs told ET.

The three new patented active ingredients are Tetrahydrocurcuminoids (THC), Coleus oil and ZeaLutien, which are set to revolutionise the dermatology, infective and geriatric ophthalmology markets.

Tetrahydrocurcuminoids are the white curcuminoids converted from the yellow active ingredient from turmeric. The component has significant anti-oxidant application and UV protection. The process of conversion from yellow to white improves bioavailability and eliminates the staining properties of curcuminoids.

The process of stabilisation of lutein (one of the 600 naturally occuring fat-soluble antioxidant carotenoid biochemicals that are found in green leafyvegetables such as spinach) immproves the longevity of the drug and its prevetion of ARMD Oil extracted from Coleus Forskohli has strong anti-microbial properties especially in fighting gram positive infections and dental microbial activity. It is superior to tree oil popularly used in India. The ingredients in nutraceuticals and cosmeceuticals formulations have a combined estimated market size of Rs 20 crore. Sami Labs plans to capture 5% of the market in the next three years with these discoveries.

The company firmly believes that patents drive discovery and innovation – reflected in its own strategy of research based intellectual property and opportunities to scale up its operations, said Dr Majeed.

Sami Labs at present has a total of 27 international patents –nine approved, three allowed and 15 more pending, he added.
“ The Indian business environment is challenging for us, especially in the absence of strong protection laws against infringement of intellectual property,” he said and added that the patents and exclusive marketing rights strengthen the product life cycle and provide patient populations an access to better healthcare solutions.

The company is also pursuing the aromas and fragrances market in India, pegged at Rs 1,200 crore.